Drug Profile
Innacell gamma-delta therapy
Latest Information Update: 10 Jul 2017
Price :
$50
*
At a glance
- Originator Innate Pharma
- Class Antineoplastics; Cell therapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Renal cancer
Most Recent Events
- 10 Jul 2017 Discontinued - Phase-I for Renal cancer in France (unspecified route)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Renal-cancer in France
- 12 Jul 2005 Innacell gamma-delta therapy is available for partnering (http://www.innate-pharma.com)